|
gptkbp:instanceOf
|
gptkb:drug
small molecule
MEK inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:neurofibromatosis_type_1
2020
|
|
gptkbp:ATCCode
|
gptkb:L01EE04
|
|
gptkbp:brand
|
gptkb:Koselugo
|
|
gptkbp:CASNumber
|
606143-52-6
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity to selumetinib
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredBy
|
gptkb:Array_BioPharma
|
|
gptkbp:eliminationHalfLife
|
5.6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
QXJYYZQYKJYFHO-RUZDIDTESA-N
|
|
gptkbp:hasMolecularFormula
|
C17H15BrClFN4O3
|
|
gptkbp:hasPatent
|
CA2509642C
EP1581982B1
US20100280013A1
WO2004061047A1
|
|
gptkbp:hasSMILES
|
COc1cc2c(cc1Cl)nc(nc2Br)N[C@@H](CO)C(=O)N
|
|
gptkbp:hasUNII
|
3W8Q1SJW2W
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Selumetinib
|
|
gptkbp:indication
|
pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits MAPK/ERK pathway
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
457.68 g/mol
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:PubChem_CID
|
10127622
DB11760
8292542
CHEMBL1201196
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
fatigue
rash
elevated liver enzymes
increased creatine phosphokinase
|
|
gptkbp:synonym
|
ARRY-142886
AZD6244
|
|
gptkbp:target
|
gptkb:MEK1
gptkb:MEK2
|
|
gptkbp:bfsParent
|
gptkb:MAP2K1
gptkb:MEK1/2
gptkb:MAPKK1
gptkb:Mitogen-activated_protein_kinase_kinase_1
gptkb:Mitogen-activated_protein_kinase_kinase_2
|
|
gptkbp:bfsLayer
|
7
|